Arm 1: Il13Ra2-Specific Car Tcm Cells
Recurrent WHO Grade III Glioma
City of Hope Medical CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
22 Active assets in the Recurrent WHO Grade III Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Virginia Commonwealth University | Phase 2 | BB |
Everolimus Nationwide Children's Hospital | Phase 2 | B |
Fycompa Mayo Clinic | Phase 4 | B |
Pamiparib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1/2 | B |
Capecitabine M.D. Anderson Cancer Center | Phase 2 | B |
View all 38 →
Same molecule, other indications
Arm 1: Il13Ra2-Specific Car Tcm Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →